BCL2L1 and uveal melanoma: Based on this observation and considering the high Bcl-2 expression in UM and the occurrence of liver metastases in its natural history, we have evaluated the therapeutic potential of a new experimental Bcl-2/Bcl-XL inhibitor, S44563, in different uveal melanoma Patient-Derived Xenografts (PDXs), and derived-cell lines, alone or in combination with fotemustine.